Steve Hoffman, Co-Founder, Chief Executive and Chief Science Officer, stated, “Our listing on NASDAQ is a major corporate milestone for Tyme, and I’m extremely pleased with the significant progress we have made over the past few years with advancing the clinical development of our lead oncology candidate SM-88. We believe that listing on NASDAQ will help broaden and diversify our shareholder base, provide better liquidity and ultimately contribute to our ability to increase shareholder value.”
Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Our lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and we are preparing to initiate an additional Phase II clinical trial for pancreatic cancer. For more information, visit our website: www.tymeinc.com.